Kaleido Biosciences, announced on 6/25/2018 that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, along with Kaleido’s founder, Flagship Pioneering, and a number of undisclosed investors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,